His dire warning pertains to a mixture of machine-learning AI and rather "vulnerable" systems that lay the foundation of the internet. Musk said that the future of cyber warfare may not be waged with humans and our weapons, but with AI systems. Just recently, an unknown group of hackers launched a massive "distributed denial of service" (DDoS) attack that took down part of the internet in the West. Analysis of the incident confirmed that the hackers used a huge "botnet," or a system of computers, that comprised simple internet of things (IoT) devices to overload the systems of Dynamic Network Services (Dyn), a firm that is part of the internet address system. These systems provide DNS services to websites, both big and small, such as Spotify, Netflix, Twitter, and Reddit.

I am not working in the health-care field, but I met several people who are working at the intersection between machine learning and health-care. Mias Lab) focusses on collecting and integrating omics data from various online databases and resources to predict risk factors for certain diseases. And Samantha Kleinberg, Author of Why, is doing remarkable research, applying and developing various statistical modeling techniques related to health care (Samantha Kleinberg). Looking at the biomedical literature, I think that the classic approach for characterizing the function of a particular protein or gene is to look at it in isolation (knocking it out or overexpressing) to link it to a certain phenotype. This bottom-up approach is certainly necessary to identify the key players related to health.

There have been tremendous advances made in making machine learning more accessible over the past few years. Online courses have emerged, well-written textbooks have gathered cutting edge research into an easier to digest format and countless frameworks have emerged to abstract the low level messiness associated with building machine learning systems. In some cases these advancements have made it possible to drop an existing model into your application with a basic understanding of how the algorithm works and a few lines of code. However, machine learning remains a relatively'hard' problem. There is no doubt the science of advancing machine learning algorithms through research is difficult.

The study was a success: the first two AIs learnt how to communicate securely from scratch. P input plaintext, K shared key, C encrypted text, and PEve and PBob are the computed plaintext outputs.The Google Brain team (which is based out in Mountain View and is separate from in London) started with three fairly vanilla neural networks called Alice, Bob, and Eve. Each neural network was given a very specific goal: Alice had to send a secure message to Bob; Bob had to try and decrypt the message; and Eve had to try and eavesdrop on the message and try to decrypt it. Alice and Bob have one advantage over Eve: they start with a shared secret key (i.e. this is symmetric encryption). Importantly, the AIs were not told how to encrypt stuff, or what crypto techniques to use: they were just given a loss function (a failure condition), and then they got on with it.

Brains have been associated with the field of artificial intelligence for more than half a century. The reason is simple: the brain is the best and perhaps only example we have of an intelligent system. But should the brain serve as mere inspiration or can it be a roadmap, providing the most efficient path to machine intelligence? More than 50 years ago artificial neural networks, or ANNs for short, were created with the intent of designing something that, like the brain, could learn without expert rules or human supervision. However, ANNs were designed at a time when little was known about how neurons worked in the brain.

Deep learning continues to gather steam in corporate computing, and IBM and Nvidia are teaming up to help accelerate the foundation behind artificial intelligence breakthroughs. The two companies are collaborating on a deep learning solution that melds technology from both companies in a bid to speed up the process of training computers to think and learn more like humans do. A new software toolkit available today called IBM PowerAI is designed to run on the recently announced IBM server built for artificial intelligence that features Nvidia NVLink technology optimized for IBM's Power Architecture. The hardware-software solution provides more than two times the performance of comparable servers with four graphics processing units (GPUs) running AlexNet with Caffe. The same four-GPU Power-based configuration running AlexNet with BVLC Caffe can also outperform 8-M40 GPU-based x86 configurations, making it the world's fastest commercially available enterprise systems platform on two versions of a key deep learning framework, the companies said.

IBM introduces Intu, new AI form which enables developers to embed supercomputer Watson functionality into numerous end-user devices, providing an advanced architecture for creating cognitive-enabled experiences. In IBM's speech, "cognitive computing" describes machine learning. The idea about Project Intu is that developers will have the chance to use the platform to embed the various machine learning features offered by IBM's Watson service into different applications and products, and make them work across a wide range of form variables. Intu makes easier the process for developers wanting to develop cognitive expertises in various form factors such as spaces, characters, bots or other IoT devices, and it extends cognitive techniques into the real world. The system enables devices to interact more naturally with users, causing different feelings and behaviors and making more significant and immersive experience for users.

Samsung Electronics Co. is making a drive for control of the car. The South Korean smartphone maker said Monday that it would buy U.S. auto-parts supplier Harman International Industries Inc., based in Stamford, Conn., for $8 billion in an all-cash deal that instantly makes Samsung a major player in the world of automotive technology. The deal -- Samsung's biggest acquisition in its history -- reshapes the pecking order in the global automotive supply chain, reflecting a quickening pace of innovation and an increased role for companies with deep pockets and a keen understanding of mobile services. Harman, an audio pioneer that dates back to 1953, has in recent years pushed aggressively into the automotive world under CEO Dinesh Paliwal, and has secured billions in new business, including big contracts with General Motors Co. and Fiat Chrysler Automobiles NV. It has projected an order backlog of $24 billion, more than three times annual revenue, and about two-thirds of its current sales come from auto makers.

IBM: AI Should Stand For'Augmented Intelligence' In response to a White House request for information about how to utilize artificial intelligence (AI) for the public good, IBM argues we should focus on a different sort of AI, augmented intelligence. In May, the White House Office of Science and Technology Policy announced a series of workshops focused on advances in AI, to explore the benefits and challenges of the technology, while also committing to the deployment of AI to improve government services. AI has made great strides in the past few years, after decades of unfulfilled promise. It's hard to find a major technology company today that isn't looking at AI-related disciplines like machine learning, natural language processing, image recognition, and neural networks as potential sources of growth, efficiency, and innovation. Everyone working with information technology, if not already dealing with some form of AI, can expect to be doing so soon.

BenevolentAI has acquired an exclusive licence for the novel clinical stage candidates, having first used its AI technology to assess their potential. It continues the firm's move into territory more often associated with IT heavyweights like Google and its DeepMind Health unit or IBM and its Watson technology. BenevolentAI's deal with J&J's Janssen Pharmaceutica NV company focuses on hard to treat diseases and will allow it to select a number of small molecule compounds, along with their patent portfolio. BenevolentAI will then have the sole right to develop, manufacture and commercialise these novel drug candidates in all indications and in all territories. The London-based firm said the agreement would enable it to accelerate its development pipeline and use its artificial intelligence technology to provide a rich source of clinical data.